Thus, further work characterizing the impact of decreasing maternal myostatin levels on fetal musculoskeletal outcomes remains to be undertaken, and a continued awareness that the wide genetic and phenotypic variability that characterizes OI may require multiple treatment approaches to adequately improve associated musculoskeletal deficits. This evidence concerns the gene MSTN and osteogenesis imperfecta.